
Please try another search
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Name | Age | Since | Title |
---|---|---|---|
Praveen Tyle | 63 | 2008 | Independent Chairman of the Board |
David A. Hollander | 49 | 2021 | Independent Director |
Erin Parsons | 48 | 2022 | Non-Employee Independent Director |
Lisa Walters-Hoffert | 65 | 2024 | Independent Director |
Aron Shapiro | 47 | 2021 | Director |
Mark Pennesi | - | 2023 | Member of Scientific Advisory Board |
Charlie Wykoff | - | - | Member of Scientific Advisory Board |
Christine Kay | - | - | Member of Scientific Advisory Board |
Carmine N. Stengone | 49 | 2023 | Independent Director |
Robert Casson | - | 2024 | Member of Advisory Board |
Roger A. Goldberg | - | 2024 | Member of Scientific Advisory Board |
Brian M. Strem | 45 | 2021 | President, CEO & Director |
Allen C. Ho | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review